The litigation, initiated by the firm Schall, Brown & Schwartz LLP, targets Aardvark Therapeutics for alleged violations of the Securities Exchange Act of 1934. According to the complaint, the company issued false and misleading statements to the market regarding the safety profile of its ARD-101 drug candidate. Plaintiffs claim that management overstated both the clinical and commercial potential of the asset throughout the period following the company’s February 2025 initial public offering.
In section Releases
Aardvark Therapeutics Faces Securities Fraud Class Action Lawsuit
Investors who purchased Aardvark Therapeutics stock between February 13, 2025, and May 14, 2026, face an October 13, 2026, deadline to seek lead plaintiff status in a newly filed federal class action lawsuit alleging securities fraud violations.
Investors who incurred financial losses during the specified class period may contact attorneys Brian Schall or David Schwartz to discuss potential recovery options. The firm notes that while the class has not yet been formally certified, shareholders retain the right to participate as absent members or seek an active role in the proceedings. Inquiries regarding the case or legal representation can be directed to the firm's Los Angeles office or through their official website.
Comments (0)
No comments yet. Be the first!